292 related articles for article (PubMed ID: 12357363)
1. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia.
Schwänen C; Hecker T; Hübinger G; Wölfle M; Rittgen W; Bergmann L; Karakas T
Leukemia; 2002 Oct; 16(10):2096-105. PubMed ID: 12357363
[TBL] [Abstract][Full Text] [Related]
2. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.
Chow KU; Boehrer S; Geduldig K; Krapohl A; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2001 May; 86(5):485-93. PubMed ID: 11410411
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced apoptosis in chronic lymphocytic leukemia.
Stoetzer OJ; Pogrebniak A; Scholz M; Pelka-Fleischer R; Gullis E; Darsow M; Nüssler V; Wilmanns W
Leukemia; 1999 Nov; 13(11):1873-80. PubMed ID: 10557065
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
Nückel H; Frey UH; Röth A; Dührsen U; Siffert W
Eur J Pharmacol; 2005 May; 514(2-3):217-24. PubMed ID: 15910809
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
[TBL] [Abstract][Full Text] [Related]
7. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells.
Santini V; Gozzini A; Scappini B; Caporale R; Zoccolante A; Rigacci L; Gelardi E; Grossi A; Alterini R; Ferrini PR
Haematologica; 1999 Oct; 84(10):897-904. PubMed ID: 10509037
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.
McConkey DJ; Chandra J; Wright S; Plunkett W; McDonnell TJ; Reed JC; Keating M
J Immunol; 1996 Apr; 156(7):2624-30. PubMed ID: 8786328
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance.
Thomas A; El Rouby S; Reed JC; Krajewski S; Silber R; Potmesil M; Newcomb EW
Oncogene; 1996 Mar; 12(5):1055-62. PubMed ID: 8649796
[TBL] [Abstract][Full Text] [Related]
11. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
Bannerji R; Kitada S; Flinn IW; Pearson M; Young D; Reed JC; Byrd JC
J Clin Oncol; 2003 Apr; 21(8):1466-71. PubMed ID: 12697868
[TBL] [Abstract][Full Text] [Related]
12. Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism.
Mengubas K; Riordan FA; Bravery CA; Lewin J; Owens DL; Mehta AB; Hoffbrand AV; Wickremasinghe RG
Oncogene; 1999 Apr; 18(15):2499-506. PubMed ID: 10229201
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines.
Konstantinov SM; Kostovski A; Topashka-Ancheva M; Genova M; Berger MR
J Cancer Res Clin Oncol; 2002 May; 128(5):271-8. PubMed ID: 12029443
[TBL] [Abstract][Full Text] [Related]
14. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
[TBL] [Abstract][Full Text] [Related]
16. N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.
Bruno S; Ghiotto F; Tenca C; Mazzarello AN; Bono M; Luzzi P; Casciaro S; Recchia A; Decensi A; Morabito F; Fais F
Leukemia; 2012 Oct; 26(10):2260-8. PubMed ID: 22475870
[TBL] [Abstract][Full Text] [Related]
17. ZGDHu-1 promotes apoptosis of chronic lymphocytic leukemia cells.
Qiu LN; Zhou YL; Wang ZN; Huang Q; Hu WX
Int J Oncol; 2012 Aug; 41(2):533-40. PubMed ID: 22581170
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
Niederle N; Megdenberg D; Balleisen L; Heit W; Knauf W; Weiß J; Freier W; Hinke A; Ibach S; Eimermacher H
Ann Hematol; 2013 May; 92(5):653-60. PubMed ID: 23340738
[TBL] [Abstract][Full Text] [Related]
19. Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients.
Scamardella F; Maconi M; Albertazzi L; Gamberi B; Gugliotta L; Brini M
Lab Hematol; 2006; 12(4):187-92. PubMed ID: 17118768
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
Glode AE; Jarkowski A
Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]